Ke Peng

8.2k citations
157 papers · 5.8k · 1 hit paper · h-index 39

Impact in

Papers in

Ke Peng

152 papers receiving 5.8k citations

Ke Peng's Hit Papers

Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension 2020 · 234 citations
2340+2+4Years since publication50100150200

Peers

Ke Peng
Comparison fields: 5 of 170
  • Pharmaceutical Science 961
  • Molecular Medicine 379
  • Virology 341
  • Infectious Diseases 928
  • Biomaterials 703
Replace Zhengrong Cui with:
Zhengrong Cui United States
Niren Murthy United States
Xianfeng Chen China
Daniel G. Anderson United States
Yu‐Kyoung Oh South Korea
Gerhard Winter Germany
Bhavesh D. Kevadiya United States
Shyam S. Mohapatra United States
Alaa A. A. Aljabali Jordan
Takeshi Mori Japan
Ke Peng relative to Zhengrong Cui United States Zhengrong Cui's profile →
Citations per field
00.5×3.2×
Zhengrong Cui · 1×
Citations per year

Countries citing papers authored by Ke Peng

Since Specialization
Citations

This map shows the geographic impact of Ke Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Peng more than expected).

Fields of papers citing papers by Ke Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ke Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Peng. The network helps show where Ke Peng may publish in the future.

Co-authors

The 25 scholars most cited alongside Ke Peng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ke Peng Line = papers co-authored together Ke Peng links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 157 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2011441
2 2011321
3 2020259
4
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension
Hit paper breakdown →
2020234
5 2020226
6 2010206
7 2011198
8 2017186
9 2019143
10 2014131
11 2020119
12 2020116
13 2021106
14 2011101
15 202193
16 202093
17 201085
18 200975
19 201974
20 201774

About Ke Peng

Ke Peng is a scholar working on Molecular Biology, Infectious Diseases, Pharmaceutical Science, Materials Chemistry and Immunology, having authored 157 papers that have together received 5.8k indexed citations. Recurring topics across this work include Advancements in Transdermal Drug Delivery (17 papers), Advanced Drug Delivery Systems (13 papers), Viral Infections and Vectors (12 papers), Dermatology and Skin Diseases (10 papers), interferon and immune responses (9 papers), HIV/AIDS drug development and treatment (8 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Supramolecular Self-Assembly in Materials (8 papers). The work is most often cited by research in Pharmaceutical Science (961 citations), Molecular Medicine (379 citations), Virology (341 citations), Infectious Diseases (928 citations) and Biomaterials (703 citations). Ke Peng has collaborated with scholars based in China, United Kingdom and Netherlands. Frequent co-authors include Alexander Kros, Itsuro Tomatsu, Zhong Zhang, Ryan F. Donnelly, Lalitkumar K. Vora, Shufen Li, Ismaiel A. Tekko, Luqi Liu, Xinglong Gong and Yu Jia. Their work appears in journals such as International Journal of Pharmaceutics, Journal of Virology, Journal of Controlled Release, ACS Applied Materials & Interfaces and ACS Applied Bio Materials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact